US SB373 | 2011-2012 | 112th Congress
Status
Spectrum: Partisan Bill (Democrat 6-0)
Status: Introduced on February 16 2011 - 25% progression, died in committee
Action: 2011-02-16 - Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
Pending: Senate Health, Education, Labor, And Pensions Committee
Text: Latest bill text (Introduced) [PDF]
Status: Introduced on February 16 2011 - 25% progression, died in committee
Action: 2011-02-16 - Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
Pending: Senate Health, Education, Labor, And Pensions Committee
Text: Latest bill text (Introduced) [PDF]
Summary
Fair Prescription Drug Competition Act - Amends the Federal Food, Drug, and Cosmetic Act to prohibit a holder of a new, approved drug application from commencing to manufacture, market, sell, or distribute a generic version of such drug from the time of the receipt of notice from the generic manufacturer that an abbreviated new drug application has been submitted for approval until the expiration or forfeiture of the 180-day exclusivity period granted to the generic manufacturer.
Title
Fair Prescription Drug Competition Act
Sponsors
| Sen. John Rockefeller [D-WV] | Sen. Daniel Inouye [D-HI] | Sen. Patrick Leahy [D-VT] | Sen. Charles Schumer [D-NY] |
| Sen. Jeanne Shaheen [D-NH] | Sen. Debbie Stabenow [D-MI] |
History
| Date | Chamber | Action |
|---|---|---|
| 2011-02-16 | Senate | Read twice and referred to the Committee on Health, Education, Labor, and Pensions. |
| 2011-02-16 | Senate | Sponsor introductory remarks on measure. (CR S797) |
Same As/Similar To
HB741 (Related) 2011-02-28 - Referred to the Subcommittee on Health.
Subjects
US Congress State Sources
| Type | Source |
|---|---|
| Summary | https://www.congress.gov/bill/112th-congress/senate-bill/373/all-info |
| Text | https://www.congress.gov/112/bills/s373/BILLS-112s373is.pdf |
